Outside advisers to the US Food and Drug Administration have recommended relaxing restrictions on a series of popular peptide compounds sought after in wellness circles.
The advisory panel delivered its recommendations following a two-day meeting designed to help determine whether the compounds could become available through specialised compounding pharmacies across the country.
Seven experimental peptide therapies came under scrutiny during the session, including some of the most widely discussed compounds in the wellness and biohacking space.
Among those reviewed were TB-500, BPC-157, and MOTs-C, none of which have undergone the large-scale clinical trials required for standard FDA drug approvals.
Despite the absence of formal approval, these therapies have attracted significant attention, promoted for uses including injury recovery, muscle growth, fat loss, skin health, and metabolic enhancement.
Thursday’s agenda included votes on four specific compounds: BPC-157, KPV, TB-500, and MOTs-C, with Friday’s session covering Emideltide, Epitalon, and Semax.
The committee was asked to review data supporting use of these peptides for conditions including migraines, ulcerative colitis, opioid withdrawal, and wound healing.
If the FDA ultimately moves to reclassify the substances, clinicians would retain discretion to write prescriptions well beyond those narrow indications.
The FDA’s own career scientists had been recommending against granting compounding pharmacies the green light to produce any of the seven peptides under consideration, putting them at odds with the advisory panel’s direction.
Ahead of the meeting, the agency had already moved to reclassify 12 drug substances from their previously restricted status, signalling a potential reversal of a 2023 decision.
The advisory committee’s convening follows Health and Human Services Secretary Robert F. Kennedy Jr. telling podcaster Joe Rogan he is a “big fan” of peptides, reflecting broader political momentum behind expanded access.
Kennedy has been a prominent voice pushing for greater availability of these compounds as part of a wider focus on alternative and preventive health approaches.
The FDA’s Pharmacy Compounding Advisory Committee discussions mark a significant moment in the ongoing debate over how unapproved but widely used substances should be regulated.
While the advisory panel’s recommendations carry considerable weight, final authority over whether to approve compounded peptide products rests with FDA leadership.